Literature DB >> 18086855

Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.

David N Taylor1, Robin McKenzie, Anna Durbin, Colleen Carpenter, Robert Haake, A Louis Bourgeois.   

Abstract

Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18086855      PMCID： PMC2258548          DOI： 10.1128/AAC.01108-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Ferrieri; A Venturi; C Brignola; M Ferretti; S Peruzzo; M Miglioli; M Campieri
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

2.  Rifaximin systemic absorption in patients with ulcerative colitis.

Authors:  F Rizzello; P Gionchetti; A Venturi; M Ferretti; S Peruzzo; X Raspanti; M Picard; N Canova; E Palazzini; M Campieri
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

3.  Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

Authors:  P Gionchetti; F Rizzello; A Venturi; F Ugolini; M Rossi; P Brigidi; R Johansson; A Ferrieri; G Poggioli; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  1999-06       Impact factor: 8.171

4.  In vitro activity and fecal concentration of rifaximin after oral administration.

Authors:  Z D Jiang; S Ke; E Palazzini; L Riopel; H Dupont
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

5.  Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.

Authors:  David N Taylor; Robin McKenzie; Anna Durbin; Colleen Carpenter; Christophe B Atzinger; Robert Haake; A Louis Bourgeois
Journal:  Clin Infect Dis       Date:  2006-03-22       Impact factor: 9.079

6.  Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

Authors:  J J Descombe; D Dubourg; M Picard; E Palazzini
Journal:  Int J Clin Pharmacol Res       Date:  1994
  6 in total
  12 in total

Review 1.  Travellers' diarrhoea - pros and cons of different prophylactic measures.

Authors:  Angelika Wagner; Ursula Wiedermann
Journal:  Wien Klin Wochenschr       Date:  2009-10       Impact factor: 1.704

2.  Bile acids improve the antimicrobial effect of rifaximin.

Authors:  Charles Darkoh; Lenard M Lichtenberger; Nadim Ajami; Elizabeth J Dial; Zhi-Dong Jiang; Herbert L DuPont
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Authors:  S M Finegold; D Molitoris; M-L Väisänen
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 4.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

5.  Management of Acute Diarrheal Illness During Deployment: A Deployment Health Guideline and Expert Panel Report.

Authors:  Mark S Riddle; Gregory J Martin; Clinton K Murray; Timothy H Burgess; Patrick Connor; James D Mancuso; Elizabeth R Schnaubelt; Timothy P Ballard; Jamie Fraser; David R Tribble
Journal:  Mil Med       Date:  2017-09       Impact factor: 1.437

6.  Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

Authors:  M Pimentel; B D Cash; A Lembo; R A Wolf; R J Israel; P Schoenfeld
Journal:  Dig Dis Sci       Date:  2017-06-06       Impact factor: 3.199

7.  Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.

Authors:  Chad K Porter; Amanda Lynen; Mark S Riddle; Kawsar Talaat; David Sack; Ramiro L Gutiérrez; Robin McKenzie; Barbara DeNearing; Brittany Feijoo; Robert W Kaminski; David N Taylor; Beth D Kirkpatrick; A Louis Bourgeois
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

8.  Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial.

Authors:  Edford Sinkala; Kanekwa Zyambo; Ellen Besa; Patrick Kaonga; Bright Nsokolo; Violet Kayamba; Michael Vinikoor; Rabison Zulu; Martin Bwalya; Graham R Foster; Paul Kelly
Journal:  Am J Trop Med Hyg       Date:  2018-02-08       Impact factor: 2.345

9.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

10.  Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.

Authors:  Edford Sinkala; Michael Vinikoor; Kanekwa Zyambo; Ellen Besa; Bright Nsokolo; Paul Kelly
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.